In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Retrophin Inc.

www.retrophin.com

Latest From Retrophin Inc.

Pharma Tweeting: Five Twitter Moments That Highlight The Perils Of The Platform

Scrip takes a broad look at some controversial Twitter moments that pharma should be watchful of  - words once let out of the cage cannot be whistled back again.

Leadership Strategy

BridgeBio-Backed CoA Therapeutics Challenges Retrophin In Genetic Disorder PKAN

Emerging Company Profile: CoA Therapeutics plans to start a Phase I study of a CoA modulator in the rare, genetic disorder PKAN during the first quarter of 2020.

StartUps and SMEs Rare Diseases

Finance Watch: Opko's Stock Halted As Nasdaq Awaits An Explanation For SEC Pump-And-Dump Lawsuit

Public Company Edition: An SEC complaint alleges that the company, Opko CEO Frost and co-defendants bought penny stocks, pumped up their value, then dumped shares for sizeable profits. Also, Pfizer and Retrophin float debt offerings, while Zealand sells royalties and milestone fees to raise cash.

Financing Regulation

Pipeline Watch: Phase III Starts With Enzastaurin, Sparsentan And Abaloparatide

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
  • Therapeutic Areas
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Renal System
  • Alias(es)
  • Retrophin LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Retrophin Inc.
  • Senior Management
  • Stephen Aselage , CEO
    Laura M Clague, CFO
    William Rote, PhD, SVP, R&D
    Neil McFarlane, COO
    Noah L Rosenberg, MD, CMO
  • Contact Info
  • Retrophin Inc.
    Phone: (760) 260-8600
    3721 Valley Centre Dr., Ste. 200
    San Diego, CA 92130
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register